Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease

blonca9
Nov 14, 2024
1 min read

CEO Tim Sharpington describes the advances that have been made in the microbiome field over the last decade and introduces us to Microbiotica's programs.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight